SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Attention centers on Corvuss soquelitinib atopic dermatitis data, which bullish traders view as encouraging evidence for the drugs broader potential. The stocks sharp negative reaction to the presentation has prompted debate over whether investor expectations were overbuilt, with skeptics citing unanswered safety questions and longs blaming short selling.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines positive Phase 3 results for daraxonrasib and its FDA approval for metastatic pancreatic cancer remain the main focus, with traders weighing the drugs commercial potential against concerns about weaker results in some KRAS subgroups and emerging competitors. Discussion also centers on the upcoming earnings report and whether early launch performance can support the companys valuation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Strong quarterly results and managements outlook are drawing attention, with traders focused on advanced negotiations to supply natural gas to data centers and other large power users. The reaction is broadly bullish on growth prospects and rising distributions, though some investors are frustrated that the unit price has shown a muted response.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AstraZeneca CEO Sees Over $20B Potential From 2027 Drug Trial Readouts – AZN Stock Eyes Breakout After Q3 Earnings Beat

AstraZenecas quarterly results beat forecasts, while a new savings plan and optimistic comments about future pipeline readouts reinforced the growth story. Traders welcomed the results and the move above the 200-day average, highlighting the pipelines potential and improving momentum.

AstraZeneca CFO says company is developing a GLP-1 pill

AstraZeneca CFO says company is developing a GLP-1 pill...

AstraZeneca Stock Rallies on Q3 Earnings Beat, Double-Digit Oncology Growth

AstraZeneca beats Q3 2026 targets as oncology offsets Farxiga losses, backed by a $2 billion pipeline restructuring push.read more...

AstraZeneca CFO on AI, Earnings, Restructuring Plan

AstraZeneca CFO on AI, Earnings, Restructuring Plan...

Pre-Markets Spooked on Questions Regarding AI, Oil Prices

Led by the Nasdaq shedding another -2.5% (-750 points) ahead of the open, the stock market is looking at a down week of trading.

AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth

AstraZeneca beats Q3 earnings and revenue estimates as oncology sales surge 17%, offsetting generic pressure on mature drugs.

Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise

SNY beats Q3 earnings and sales estimates as Dupixent drives growth and the company raises its 2026 outlook for sales and business EPS.

Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Equity

AstraZeneca reported a 7% increase in Q3 revenue to $16.21 billion, beating Wall Street estimates of about $16 billion, according to Fiscal.ai.


FTSE 100 Modestly Higher; AstraZeneca Rises On Strong Earnings

(RTTNews) - U.K. stock market's benchmark FTSE 100 moved higher Friday morning, supported by strong results from pharma major AstraZeneca and energy giant BP. Weakness in bank and mining stocks limited market's upside...

AstraZeneca Q3 Profit Rises; Reconfirms FY26 Revenue, Core EPS Guidance At CER

(RTTNews) - AstraZeneca PLC (AZN, AZN.L, ZEG.DE, AZN.ST) reported that its third quarter profit attributable to owners of the Parent increased to $3.12 billion from $2.53 billion, prior year. Diluted earnings per $0.25 Ordinary Share was $2.00 compared to $1.62. Core EPS was $2.7...

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

Bearish Sentiment

<ul class="summary-bullets"><li>Core earnings per share increased 17% to $2.79, beating consensus estimates of $2.59.</li><li>The company announced a restructuring program targeting $1.5 billion in annual savings by 2029.</li><li>AstraZeneca reiterated its full-year 2026 guidance</li></ul><p>AstraZeneca (AZN) was in focus on Friday after CEO Pascal Soriot highlighted the potential for its 2027 drug trial readouts to generate over $20 billion in peak annual sales, while the company unveiled a restructuring program targeting $1.5 billion in annual savings by 2029.</p><p><a class="mention" data-mention="$AZN" data-symbol-id="AZN" href="https://stocktwits.com/symbol/AZN" target="_blank">AZN shares</a> were up about 5% in pre-market trading, on track to breach the 200-day moving average (200-DMA) for the first time since July.</p><p><img src="https://news.stocktwits-cdn.com/AZN_696a68eaf7.png" alt="AZN.png"></p><h2 class="st-heading-2">CEO Sees Over $20B Potential From 2027 Pipeline</h2><p>Soriot said AstraZeneca’s upcoming clinical trial results in 2027 could lead to peak annual revenue exceeding $20 billion. The company has more than 180 projects in development, including experimental treatments for cancer, respiratory illnesses, and rare diseases.</p><p>“Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars. With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition and to sustain growth through the next decade,” Soriot added.</p><h2 class="st-heading-2">Q3 Earnings Beat Driven By Oncology Revenue Growth</h2><p>AstraZeneca reported a 7% increase in third-quarter (Q3) revenue to $16.21 billion, beating Wall Street estimates of about $16 billion, according to Fiscal.ai. Core earnings per share (EPS) increased 17% to $2.79, beating consensus estimates of $2.59.</p><p>Oncology revenue jumped 17% to $7.77 billion, supported by strong sales growth for Enhertu and Imfinzi therapies. However, diabetes drug Farxiga sales fell 25% to $1.61 billion amid growing generic competition.</p><h2 class="st-heading-2">$1.5B Annual Savings Target</h2><p>The company also announced a restructuring program targeting $1.5 billion in annual savings by 2029, primarily to fund drug development. The initiative could involve up to $2 billion in one-time restructuring costs.</p><p>AstraZeneca reiterated its full-year 2026 guidance, expecting revenue to grow by a mid-to-high single-digit percentage and core EPS to increase by a low double-digit percentage at constant exchange rates.</p><h2 class="st-heading-2">Retail Turns Bearish</h2><p>Retail sentiment surrounding AZN on Stocktwits turned ‘bearish’ from ‘neutral’ despite Q3 beat, while message volumes remained ‘high.’</p><p><img src="https://news.stocktwits-cdn.com/AZN_S_c93457a253.png" alt="AZN S.png"></p><p>While AZN is on track to record its biggest monthly gains since February, the stock is down about 5% so far in 2026.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The international biopharmaceutical company AstraZeneca office building in Shanghai, China on June 27, 2025. 

AstraZeneca reported a 7% increase in Q3 revenue to $16.21 billion, beating Wall Street estimates of about $16 billion, according to Fiscal.ai.

AstraZeneca PLC

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$1.21	--	--	N/A
Q3 '26	$1.29	$1.39	7.90%	BEAT
Q2 '26	$1.25	$1.32	5.61%	BEAT
Q1 '26	$1.26	$1.29	2.39%	BEAT
Q4 '25	$1.05	$1.06	1.44%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

AZN Earnings

Latest Earnings Results: Q3 '26

Historical Earnings